Steroids and immunosuppressants are indicated to treat systemic vasculitides. However, the therapeutic strategy is different from one disease to the other. Treatment choice should be adapted to the predictable outcome, severity, pathogenic mechanisms and patient's general condition. In polyarteritis nodosa, Churg Strauss syndrome, and microscopic polyangiitis we have demonstrated that immunosuppressants should not be systematically prescribed. Immunosuppressantsshould be only prescribed in the most severe patients, when factors of poor prognosis are present. In Wegener's granulomatosis, immunosuppressantsshould be systematically prescribed together with steroids. The optimal treatment duration is of 12 months for polyarteritis nodosa and Churg-Strauss syndrome. A more prolonged treatment is mandatory in Wegener's granulomatosis, at least 18 months. The new therapeutic strategies comprise also newimmunosuppressants and new immunomodulating agents which could replace or be associated to the "older drugs"
Wegener' s granulomatosis (WG). Nevertheless, many points concerning the use of CYCremained to be clarified: dose, duration, route of administration, associated treatments. A new era has also been opened by new agents originally designed for the field of transplantation and anti-cytokines which appear to be promising drugs to treat several rheumatic diseases.
The decision to prescribe immunosuppressants should also be adapted to several factors and optimization achieved after careful analysis of classification, predictible outcome, etiology, pathogenesis, severity, age and organ(s) involved.
The prospective studies on PAN, MPAand CSS organized by the French Vasculitis Study Group (FVSG), examined the indications of CYCand, based on the results obtained and those reported in the literature, we review herein the therapeutic strategies nowbeing applied to treat severe systemic vasculitides.
Classification
Inflammation and necrosis of blood-vessel walls are characteristic of systemic vasculitides. All sizes of blood vessels from the aorta to capillaries maybe affected by the vasculitic process. Since the first description by Kiissmaul and Maier (2), different vasculitides have been identified and different classification systems have been proposed. The American College of Rheumatology has defined different classification criteria for vasculitides (3-5) but the classification that has been unanimously adopted by the scientific and medical community to differentiate PANfrom MPA,is the Chapel Hill Nomenclature (6).
Predictible Outcome
The outcome of vasculitis differs from one disease to another and the relapse rate also varies, from 5%for hepatitis B virus-related PAN (HBV-PAN) (7) to 23.4% for CSS (8), 34.1% forMPA (9) and more than 50% inWG (10, ll). The duration of treatment should probably be determined, at least in part, according to the risk of relapse. Shorter-term treatments might be suitable for mild forms of PAN, which is a "one-shot-disease", but not for the most severe forms, for Immunosuppressants are prescribed only to patients whodo not respond to the antiviral strategy, or those with glomerulonephritis associated with cryoglobulinemia vasculitis.
Disease Severity
The indications of immunosuppressants are different for WGand other systemic vasculitides.
In WG, CYCis indicated for all the patients with systemic manifestations. In other vasculitides, like PAN, CSS or MPA,the choice is not so clear and we nowrecommendadapting the treatment to disease severity.
First-line therapy
It now seemsreasonable to adapt the initial treatment to the severity of the vasculitis and not to propose systematically a standard treatment. To help the clinician choose the most effective therapy and to avoid overtreatment, we have established a five-factor score (FFS), which has significant prognostic value (16) and whose parameters, defined as below, were responsible for higher mortality: proteinuria >1 g/day, renal insufficiency (creatininemia>140 jumol/Z), cardiomyopathy, gastrointestinal (GI) manifestations and central nervous system (CNS) involvement. When FFS=0, mortality at 5 years was 12%; when FFS=1, mortality was 26%; when FFS>2, mortality was 46%. In a study on 278
patients (17) presenting with PAN, MPAor CSS, we demonstrated that the combination of CYCand CS was beneficial for patients with an FFS>2. The patients whodied from severe vasculitides had more often been treated with CS than with the combined regimen. Other criteria, like the Birmingham vasculitis activity score (BVAS) (18) , are also used to determine the intensity of treatment and are being tested in the prospective trials proposed by the European Vasculitis (EUVAS) group.
Indications of CS and CYCin PAN and CSS
The prognoses of the different vasculitides have been transformed by CS and immunosuppressive drugs, especially CYC. CS alone has increased the 5-year survival rate from 10%for untreated patients to about 55%in the mid-to-late 1970s (19) .
CS
The initial management of PANwithout HBVinfection should include high doses of CS. The administration of methylprednisolone pulses (usually 15 mg/kg IV over 60 minutes repeated at 24-h intervals for 1 to 3 days) has become widely used at the initiation of therapy for severe sys- dose, the prednisone dose should be progressively decreased and, in the absence of relapse, CScan be stopped after 9 to 12 months. Whencombined with CYC, prednisone dose tapering should be more rapid to reduce the number of infectious complications. The EUVAS group recommends the rapid tapering of the prednisone dose for all antineutrophilcytoplasm antibody (ANCA)-associated vasculitides.
Decreasing treatment intensity while maintaining the therapeutic effect is now a major concern for clinicians, since it is likely that some patients have been overtreated. It is probable that patients without factors of poor prognosis (FFS=0) at the time of diagnosis could be successfully treated with prednisone alone and CYCadministered only as the second-line treatment in the case of persistent disease activity or relapse despite CS therapy. A similar therapeutic scheme was tested in one of our previous trials (20) . Despite the high relapse rate observed in patients treated with prednisone alone, the 7-year survival rate was 79%, very similar to that observed for other patients also receiving immunosuppressive agents.
CYC
For PANand CSSpatients with factors of poor prognosis (FFS>1) (16), CYC is indicated and IV pulses should be preferred to oral administration (21) . The IV route gives a more rapid clinical response than oral CYCwhich is important in patients with active disease. Whencompared, the two CYC regimens were equally effective at controlling disease activity. Oral CYChas been successfully introduced when IV pulses failed to control disease activity or for relapse within the first 6 months of treatment (22). Treatment duration with CS and CYCshould not exceed 1 year. To reduce toxicity resulting from prolonged CYCtherapy, shorter therapeutic protocols were evaluated (23) and, for severe PAN/MPA, a regimen comprising 12 pulses of CYCprovided better control; and fewer relapses and deaths occurred. Pulse CYC therapy is now being used more frequently for systemic necrotizing vasculitis and should, in our opinion, be preferred over oral CYC,for first-line therapy. The CYCcontent of each pulse, as well as the total number and frequency of the pulses, should be adjusted to the patient's condition, renal function, hematological data and the disease' s response to prior therapies, including previous CYCpulses. The CYCpulse dose recommended in our protocols is 0.6 g/m2 delivered monthly for 1 year. Higher IV CYCdoses may be particularly dangerous in patients with renal insufficiency, suggesting that dose adjustment according to renal function would be prudent (24) Intense hydration and, for some authors, the use of sodium 2-mercapto-ethanesulfonate (mesna) are recommendedduring pulse therapy, despite some sometimes severe allergic reactions. Pulse CYCtherapy allows a lower cumulative dose to be given and exposes the patient to less potential toxicity for shorter periods.
Treatment of WG
CS are common to every treatment regimen for systemic vasculitides.
We will therefore concentrate on cytotoxic agents. For WG,a consensus has not yet been reached concerning CYC, even though its indication is universally accepted. The oral route is prescribed at 2 mg/kg/d (10). The dose should adapted according to the therapeutic response, the occurrence of side effects, renal function and age. The overall treatment duration for WGvaries but should last at least 18 months and should reflect the therapeutic strategy applied and maintenance regimen choices. EUVAS group obtained equivalent results with 3 months of oral CYCfollowed by 12 months azathioprine or 12 months of oral CYC (25).
CYCpulses, have also been used every 3 to 4 weeks, 0.5 to 0.7 g/m2 (ll, 26). The clinical results were comparable and showed that administration gave results comparable to those observed with the oral route. However, the number of relapses was high after stopping treatment (1 1). In our opinion, pulse treatment is effective in obtaining remission but is not able to maintain it. Other therapeutic strategies should therefore be prescribed to maintain remission. Should pulses fail, oral CYCcan be given successfully. Conversely, pulse CYCis usually less or not effective whenadministered after failure of oral treatment.
Although oral CYC is effective for the treatment of vasculitic disease, it has a low therapeutic/toxic index and severe side effects minimize the therapeutic benefit of using it. Major side effects associated with daily CYCadministration include hemorrhagic cystitis, bladder fibrosis, bonemarrowsuppression, ovarian failure, neoplasm (bladder cancer and hematological malignancies). prescription of PE at the time of diagnosis of PANwithout HBVinfection, even for patients with factors of poor prognosis. However, PE can be a useful tool, as second-line treatment, in PAN refractory to conventional therapy. For patients with crescentic glomerulonephritis responsible for severe renal insufficiency (creatininemia>500 |Lxmol//), Pusey and coworkers (28), unlike others, consider that PE can improve renal function and enable patients to stop dialysis. This hypothesis is now being tested through a prospective controlled trial comparing patients ANCA-positive vasculitides and presenting renal insufficiency (>500 jumol//) at entry.
The preliminary results of EUVAS group prospective trial showedthat, at 3 months, the numberof dialysis-dependent patients was significantly lower in the PE-group treated vs the group receiving methylprednisolone pulses (unpublished data). Those results need to be confirmed by the final analy- 
